Skip to main
CRBP
CRBP logo

CRBP Stock Forecast & Price Target

CRBP Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 54%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Corbus Pharmaceuticals Holdings Inc. benefits from its diverse and innovative pipeline, particularly the promising early-stage data for CRB-701, which demonstrates a favorable risk-benefit profile and an impressive overall response rate of approximately 44% in cervical cancer, surpassing that of its competitors. Furthermore, CRB-601 shows strong potential due to its attractive preclinical evidence and ability to inhibit TGF activation within the tumor microenvironment, suggesting significant upside against key market players. The favorable early clinical data coupled with a competitive edge in safety profiles positions Corbus for potential growth, reinforcing a positive outlook on its stock performance.

Bears say

Corbus Pharmaceuticals Holdings Inc faces a negative outlook primarily due to significant concerns regarding regulatory approval for its key drug candidates, which could lead to adverse impacts on the company's share price if timelines are delayed or unmet. Additionally, the company's focus on CRB-913 is viewed as misplaced, particularly in light of comparisons to Novo Nordisk's therapeutic developments, which could inflate market expectations. Furthermore, safety concerns, particularly regarding ocular toxicity associated with Tivdak, may hinder its acceptance and adherence among patients, ultimately affecting the company's financial performance.

CRBP has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 54% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corbus Pharmaceuticals Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corbus Pharmaceuticals Holdings (CRBP) Forecast

Analysts have given CRBP a Buy based on their latest research and market trends.

According to 13 analysts, CRBP has a Buy consensus rating as of Jul 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corbus Pharmaceuticals Holdings (CRBP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.